Literature DB >> 19081173

Alterations in CIITA constitute a common mechanism accounting for downregulation of MHC class II expression in diffuse large B-cell lymphoma (DLBCL).

Kelly A Cycon1, Lisa M Rimsza, Shawn P Murphy.   

Abstract

OBJECTIVE: Significant decreases in patient survival are associated with downregulation of major histocompatibility complex class II (MHC-II) antigen expression in diffuse large B-cell lymphoma (DLBCL). However, the molecular mechanisms responsible for decreased MHC-II expression in DLBCL are poorly defined. We therefore examined these mechanisms in established DLBCL cell lines.
MATERIALS AND METHODS: Human leukocyte antigen (HLA)-DR surface expression was examined by flow cytometry. Expression of the MHC-II genes and the MHC-II transcriptional activators class II transactivator (CIITA) and RFX was investigated by reverse transcriptase polymerase chain reaction. The integrity of the MHC-II genes was examined by polymerase chain reaction. Stable transfection assays were utilized to reconstitute CIITA expression.
RESULTS: Dramatic variations in the levels of cell surface HLA-DR expression were observed on the DLBCL cell lines. OCI-Ly10 cells lack HLA-DR and HLA-DQ expression due to homozygous deletions within the MHC-II locus on chromosome 6. Dyscoordinate downregulation of MHC-II beta-chain expression in OCI-Ly3 cells mediates dramatic reductions of MHC-II surface expression. In SUDHL-4 and SUDHL-6 cells, expression of the MHC-II genes is coordinately reduced and quantitatively correlated with expression of the CIITA, the master regulator of MHC-II transcription. DB cells lack expression of CIITA and all of the MHC-II genes. Stable transfection of DB cells with CIITA expression vectors resulted in coordinate upregulation of MHC-II gene expression, which demonstrates the causal relationship between the lack of CIITA and MHC-II loss.
CONCLUSIONS: These data demonstrate that downregulation of MHC-II expression occurs by multiple distinct mechanisms in DLBCL. However, decreases in CIITA expression appear to be the most prevalent mechanism.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19081173     DOI: 10.1016/j.exphem.2008.10.001

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  20 in total

1.  Genomic Analyses Identify Recurrent Alterations in Immune Evasion Genes in Diffuse Large B-Cell Lymphoma, Leg Type.

Authors:  Xiaolong Alan Zhou; Abner Louissaint; Alexander Wenzel; Jingyi Yang; Maria Estela Martinez-Escala; Andrea P Moy; Elizabeth A Morgan; Christian N Paxton; Bo Hong; Erica F Andersen; Joan Guitart; Amir Behdad; Lorenzo Cerroni; David M Weinstock; Jaehyuk Choi
Journal:  J Invest Dermatol       Date:  2018-05-30       Impact factor: 8.551

Review 2.  Dysfunction of antigen processing and presentation by dendritic cells in cancer.

Authors:  Joanna Bandola-Simon; Paul A Roche
Journal:  Mol Immunol       Date:  2018-04-05       Impact factor: 4.407

3.  Coordinate loss of MHC class II expression in the diffuse large B cell lymphoma cell line OCI-Ly2 is due to a novel mutation in RFX-AP.

Authors:  Meghan Bushway; Kelly A Cycon; Kathleen Mulvaney; Shawn P Murphy
Journal:  Immunogenetics       Date:  2009-12-19       Impact factor: 2.846

4.  Tumor-associated macrophages in diffuse large B-cell lymphoma.

Authors:  Robert Kridel; Christian Steidl; Randy D Gascoyne
Journal:  Haematologica       Date:  2015-02       Impact factor: 9.941

Review 5.  Understanding and Managing Large B Cell Lymphoma Relapses after Chimeric Antigen Receptor T Cell Therapy.

Authors:  Michael Byrne; Olalekan O Oluwole; Bipin Savani; Navneet S Majhail; Brian T Hill; Fredrick L Locke
Journal:  Biol Blood Marrow Transplant       Date:  2019-07-04       Impact factor: 5.742

Review 6.  Genetic lesions in diffuse large B-cell lymphomas.

Authors:  M Testoni; E Zucca; K H Young; F Bertoni
Journal:  Ann Oncol       Date:  2015-01-20       Impact factor: 32.976

Review 7.  Structural aspects of the MHC expression control system.

Authors:  Grady Nash; Bhaskar Paidimuddala; Liman Zhang
Journal:  Biophys Chem       Date:  2022-02-15       Impact factor: 2.352

8.  Decreased major histocompatibility complex class II expression in diffuse large B-cell lymphoma does not correlate with CpG methylation of class II transactivator promoters III and IV.

Authors:  Sarah T Wilkinson; Diane R Fernandez; Shawn P Murphy; Rita M Braziel; Elias Campo; Wing C Chan; Jan Delabie; Randy D Gascoyne; Louis M Staudt; Elaine S Jaffe; Andreas Rosenwald; Lisa M Rimsza
Journal:  Leuk Lymphoma       Date:  2009-11

Review 9.  Molecular classification, pathway addiction, and therapeutic targeting in diffuse large B cell lymphoma.

Authors:  Soham Puvvada; Samantha Kendrick; Lisa Rimsza
Journal:  Cancer Genet       Date:  2013-09-27

10.  Histone deacetylase inhibitors activate CIITA and MHC class II antigen expression in diffuse large B-cell lymphoma.

Authors:  Kelly A Cycon; Kathleen Mulvaney; Lisa M Rimsza; Daniel Persky; Shawn P Murphy
Journal:  Immunology       Date:  2013-10       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.